DE602005025750D1 - Verbindungen zur proteasomenzymhemmung - Google Patents

Verbindungen zur proteasomenzymhemmung

Info

Publication number
DE602005025750D1
DE602005025750D1 DE602005025750T DE602005025750T DE602005025750D1 DE 602005025750 D1 DE602005025750 D1 DE 602005025750D1 DE 602005025750 T DE602005025750 T DE 602005025750T DE 602005025750 T DE602005025750 T DE 602005025750T DE 602005025750 D1 DE602005025750 D1 DE 602005025750D1
Authority
DE
Germany
Prior art keywords
peptide
compounds
proteasome
based compounds
activities
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005025750T
Other languages
English (en)
Inventor
Mark S Smyth
Guy J Laidig
Ronald T Borchardt
Barry A Bunin
Craig M Crews
John H Musser
John Clifford Chabala
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onyx Pharmaceuticals Inc
Original Assignee
Proteolix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005025750(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Proteolix Inc filed Critical Proteolix Inc
Publication of DE602005025750D1 publication Critical patent/DE602005025750D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
DE602005025750T 2004-04-15 2005-04-14 Verbindungen zur proteasomenzymhemmung Active DE602005025750D1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US56234004P 2004-04-15 2004-04-15
US56909604P 2004-05-07 2004-05-07
US59940104P 2004-08-06 2004-08-06
US61000204P 2004-09-14 2004-09-14
US61015904P 2004-09-14 2004-09-14
US61000104P 2004-09-14 2004-09-14
US62057304P 2004-10-20 2004-10-20
PCT/US2005/012740 WO2005105827A2 (en) 2004-04-15 2005-04-14 Compounds for proteasome enzyme inhibition

Publications (1)

Publication Number Publication Date
DE602005025750D1 true DE602005025750D1 (de) 2011-02-17

Family

ID=34965899

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005025750T Active DE602005025750D1 (de) 2004-04-15 2005-04-14 Verbindungen zur proteasomenzymhemmung

Country Status (17)

Country Link
US (9) US8129346B2 (de)
EP (1) EP1745064B1 (de)
JP (3) JP5616569B2 (de)
CN (2) CN103554222A (de)
AT (1) ATE494298T1 (de)
AU (1) AU2005238445B2 (de)
BR (1) BRPI0509879A (de)
CA (1) CA2562411A1 (de)
CY (1) CY1117244T1 (de)
DE (1) DE602005025750D1 (de)
DK (1) DK1745064T3 (de)
HK (1) HK1097860A1 (de)
IL (3) IL178400A (de)
PL (1) PL1745064T3 (de)
PT (1) PT1745064E (de)
SG (2) SG185306A1 (de)
WO (1) WO2005105827A2 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012203602B2 (en) * 2004-04-15 2015-08-27 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
CA2562411A1 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for enzyme inhibition
EP2564834A3 (de) 2004-05-10 2013-08-21 Onyx Therapeutics, Inc. Verbindungen zur Proteasomenzyminhibition
EP2260835B1 (de) 2004-12-07 2013-03-06 Onyx Therapeutics, Inc. Zusammensetzung zur Proteasomhemmung
PL2623113T3 (pl) 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
BRPI0713309A2 (pt) 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
MY166950A (en) * 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы
PT2408802T (pt) 2009-03-16 2017-08-03 Governing Council Univ Toronto Moléculas de aminoácido ciclicas e métodos para as preparar
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
GB0914883D0 (en) 2009-08-26 2009-09-30 Univ Belfast Compound
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
EP2542238B1 (de) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Verbindungen zur immunproteasomhemmung
BR112012025264A2 (pt) 2010-04-07 2019-09-24 Onyx Therapeutics Inc inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
JP6410264B2 (ja) * 2012-05-08 2018-10-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドプロテアソーム阻害剤を調合するためのシクロデキストリン錯体形成法
JP2015524394A (ja) * 2012-07-09 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドエポキシケトンプロテアーゼ阻害剤のプロドラッグ
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
RU2670127C2 (ru) 2013-03-13 2018-10-18 Санофи Композиции, включающие антитела к cd38 и карфилзомиб
EP3021862B1 (de) 2013-07-19 2017-08-30 Onyx Therapeutics, Inc. Peptid-epoxyketon-proteasominhibitoren in kombination mit pim-kinasehemmern zur behandlung von krebs
CN103360348B (zh) * 2013-07-25 2015-06-24 苏州鹏旭医药科技有限公司 一种Carfilzomib中间体及其制备方法和制备Carfilzomib的方法
CN105517998A (zh) * 2013-09-06 2016-04-20 桑多斯股份公司 通过曼尼希反应立体选择性合成二醇和三醇以及它们在卡非佐米合成中的用途
WO2015032621A1 (en) * 2013-09-06 2015-03-12 Sandoz Ag Synthesis of peptide epoxy ketones
CN104710507B (zh) * 2013-12-11 2018-08-14 深圳翰宇药业股份有限公司 一种卡非佐米的制备方法
WO2015121769A1 (en) 2014-02-13 2015-08-20 Ranbaxy Laboratories Limited Process for the preparation of methyl n-[(benzyloxy)-carbonyl]-l-leucyl-l-phenylalaninate
CN105960399B (zh) 2014-07-14 2018-09-25 宁波圣健生物医药科技有限公司 酶抑制剂环氧酮化合物
WO2016046843A1 (en) 2014-09-24 2016-03-31 Biophore India Pharmaceuticals Pvt. Ltd. Process for the preparation of (s)-4-methyl-n-((s)-1-(((s)-4-methyl-1-((r)-2-methyloxiran-2-yl)-1-oxo pentan-2-yl) amino)-1-oxo-3-phenylpropan-2-yl)-2-((s)-2-(2-morpholinoacetamido)-4-phenylbutanamido) pentanamide
WO2016069479A1 (en) 2014-10-27 2016-05-06 Apicore Us Llc Methods of making carfilzomib and intermediates thereof
EP3227312B1 (de) 2014-12-02 2019-05-29 Fresenius Kabi Oncology Limited Verfahren zur reinigung von carfilzomib
EP3240575A4 (de) 2014-12-31 2018-07-25 Dr. Reddy's Laboratories Ltd. Co-kristall von carfilzomib mit maleinsäuren und verfahren zur herstellung von reinen carfilzomib
WO2016116882A2 (en) * 2015-01-23 2016-07-28 Leiutis Pharmaceuticals Pvt Ltd Novel compositions of carfilzomib
US10544189B2 (en) * 2015-04-22 2020-01-28 Msn Laboratories Private Limited Process for the preparation of (2S)-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylcarbamoyl)-2-phenylethyl)-2-((S)-2-(2-morpholinoacetamido)-4-phenylbutanamido)-4-methylpentanamide
WO2016170489A1 (en) 2015-04-24 2016-10-27 Fresenius Kabi Oncology Ltd. Pharmaceutical compositions of proteasome inhibitor
WO2016185450A1 (en) 2015-05-21 2016-11-24 Laurus Labs Private Limited An improved processes for the preparation of carfilzomib or pharmaceutically acceptable salts thereof
CA3004714A1 (en) 2015-11-11 2017-05-18 Encycle Therapeutics, Inc. Fragment synthesis of cyclic peptides
EP3494126A1 (de) 2016-08-02 2019-06-12 Synthon BV Verfahren zur herstellung von carfilzomib
ES2874683T3 (es) 2016-09-14 2021-11-05 Fresenius Kabi Oncology Ltd Un proceso para la purificación de un intermedio de carfilzomib
US11111273B2 (en) 2016-11-11 2021-09-07 Zealand Pharma A/S Cyclic peptides multimers targeting alpha-4-beta-7 integrin
EP3330260A1 (de) 2016-12-01 2018-06-06 Enantia, S.L. Verfahren zur herstellung eines zwischenprodukts zur synthese von i. a. carfilzomib
CN106946981B (zh) * 2017-03-08 2020-08-21 南京陵瑞医药科技有限公司 一种四肽环氧丙烷衍生物及其制备方法和用途
US11286281B2 (en) 2017-05-10 2022-03-29 Zealand Pharma A/S Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
EP3694878A1 (de) 2017-09-14 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Kombinationsbehandlung für krebs
CN113185575B (zh) * 2021-05-11 2022-07-12 四川大学 一种花生抗氧化多肽及其制备方法
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
JPH01136498A (ja) 1987-11-21 1989-05-29 Nec Corp 状態監視用情報伝送装置
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5441944A (en) 1989-04-23 1995-08-15 The Trustees Of The University Of Pennsylvania Substituted cyclodextrin sulfates and their uses as growth modulating agents
US5071957A (en) 1989-08-04 1991-12-10 Bristol-Myers Company Antibiotic BU-4061T
US4990448A (en) 1989-08-04 1991-02-05 Bristol-Myers Company Bu-4061T
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
EP0518955A4 (en) 1990-03-05 1993-09-22 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
US5340736A (en) 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
GB9300048D0 (en) 1993-01-04 1993-03-03 Wellcome Found Endothelin converting enzyme inhibitors
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
AU4499697A (en) 1996-09-13 1998-04-02 New York University Method for treating parasitic diseases with proteasome inhibitors
SI0932617T1 (en) 1996-10-18 2002-06-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
US6022887A (en) 1996-12-13 2000-02-08 Osteoscreen, Inc. Compositions and methods for stimulating bone growth
US6046177A (en) 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
JP4439596B2 (ja) 1997-06-13 2010-03-24 サイデクス ファーマシューティカルズ、 インク． 長期の貯蔵寿命を有する、極性薬物又は極性プロドラッグを含有する医薬組成物、及びその製造方法
US6099851A (en) 1998-06-02 2000-08-08 Weisman; Kenneth M. Therapeutic uses of leuprolide acetate
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
AU762373B2 (en) 1998-10-20 2003-06-26 Millennium Pharmaceuticals, Inc. Method for monitoring proteasome inhibitor drug action
US6492333B1 (en) 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
CA2385958A1 (en) * 1999-10-20 2001-04-26 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone and hair growth
JP2004510826A (ja) 2000-10-12 2004-04-08 ヴィローミクス　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング ウイルス感染の治療剤
US7524883B2 (en) 2002-01-08 2009-04-28 Eisai R&D Management Co., Ltd. Eponemycin and epoxomicin analogs and uses thereof
AU2003220685A1 (en) 2002-04-09 2003-10-27 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
US20030224469A1 (en) 2002-06-03 2003-12-04 Buchholz Tonia J. Methods and kits for assays utilizing fluorescence polarization
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
CA2562411A1 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for enzyme inhibition
EP2564834A3 (de) 2004-05-10 2013-08-21 Onyx Therapeutics, Inc. Verbindungen zur Proteasomenzyminhibition
US20050256324A1 (en) 2004-05-10 2005-11-17 Proteolix, Inc. Synthesis of amino acid keto-epoxides
EP2100899A3 (de) 2004-10-20 2009-09-30 Proteolix, Inc. Verbindungen zur Enzyminhibition
EP2260835B1 (de) 2004-12-07 2013-03-06 Onyx Therapeutics, Inc. Zusammensetzung zur Proteasomhemmung
WO2006099261A2 (en) 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
PL2623113T3 (pl) 2005-11-09 2018-05-30 Onyx Therapeutics, Inc. Związek do hamowania enzymu
AR057227A1 (es) 2005-12-09 2007-11-21 Centocor Inc Metodo para usar antagonistas de il6 con inhibidores del proteasoma
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
BRPI0713309A2 (pt) 2006-06-19 2012-04-17 Proteolix Inc compostos para inibição de enzimas
JP4325683B2 (ja) * 2007-02-14 2009-09-02 セイコーエプソン株式会社 画像表示装置、及び画像表示装置の制御方法
WO2008140782A2 (en) 2007-05-10 2008-11-20 Proteolix, Inc. Compounds for enzyme inhibition
MY166950A (en) 2007-10-04 2018-07-25 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EA024364B1 (ru) 2008-10-21 2016-09-30 Оникс Терапьютикс, Инк. Способ лечения множественной миеломы

Also Published As

Publication number Publication date
CA2562411A1 (en) 2005-11-10
IL178400A (en) 2012-02-29
US20130324459A1 (en) 2013-12-05
JP2012041346A (ja) 2012-03-01
AU2005238445B2 (en) 2012-05-03
CY1117244T1 (el) 2017-04-05
IL217211A0 (en) 2012-01-31
US8207124B2 (en) 2012-06-26
PT1745064E (pt) 2011-03-23
US8207127B2 (en) 2012-06-26
US20120094926A1 (en) 2012-04-19
HK1097860A1 (en) 2007-07-06
US20120094929A1 (en) 2012-04-19
IL217210A0 (en) 2012-01-31
PL1745064T3 (pl) 2011-06-30
WO2005105827A3 (en) 2006-03-30
WO2005105827A2 (en) 2005-11-10
JP2008501637A (ja) 2008-01-24
BRPI0509879A (pt) 2007-10-16
IL178400A0 (en) 2007-02-11
US8207297B2 (en) 2012-06-26
US8207125B2 (en) 2012-06-26
ATE494298T1 (de) 2011-01-15
US8207126B2 (en) 2012-06-26
US20120101048A1 (en) 2012-04-26
JP5616569B2 (ja) 2014-10-29
JP2014012676A (ja) 2014-01-23
EP1745064A2 (de) 2007-01-24
EP1745064B1 (de) 2011-01-05
SG185306A1 (en) 2012-11-29
US8324174B2 (en) 2012-12-04
US20120094930A1 (en) 2012-04-19
SG152239A1 (en) 2009-05-29
US20080200398A1 (en) 2008-08-21
AU2005238445A1 (en) 2005-11-10
US20120277146A1 (en) 2012-11-01
DK1745064T3 (da) 2011-04-11
US8129346B2 (en) 2012-03-06
US20120101050A1 (en) 2012-04-26
US20120094928A1 (en) 2012-04-19
CN103554222A (zh) 2014-02-05
CN102174076A (zh) 2011-09-07

Similar Documents

Publication Publication Date Title
DE602005025750D1 (de) Verbindungen zur proteasomenzymhemmung
DE602005026019D1 (de) Verbindungen zur proteasomenzymhemmung
EP2564834A3 (de) Verbindungen zur Proteasomenzyminhibition
MY171061A (en) Compounds for enzyme inhibition
WO2008140782A3 (en) Compounds for enzyme inhibition

Legal Events

Date Code Title Description
R097 No opposition filed against granted patent, or epo opposition proceedings concluded without decision

Ref document number: 1745064

Country of ref document: EP

Effective date: 20111006

R081 Change of applicant/patentee

Ref document number: 1745064

Country of ref document: EP

Owner name: PROTEOLIX, INC., US

Free format text: FORMER OWNER: PROTEOLIX, INC., SOUTH SAN FRANCISCO, US

Effective date: 20120216

R082 Change of representative

Ref document number: 1745064

Country of ref document: EP

R082 Change of representative

Ref document number: 1745064

Country of ref document: EP